ACELYRIN
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
ACELYRIN
Industry:
Biopharma Biotechnology Health Care
Founded:
2020-01-01
Address:
Los Angeles, California, United States
Country:
United States
Website Url:
http://www.acelyrin.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
558 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Google Tag Manager Google Analytics Content Delivery Network Amazon Global Site Tag HSTS IPv6
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-01-05 | ValenzaBio | ValenzaBio acquired by ACELYRIN | N/A |
Investors List
Westlake Village BioPartners
Westlake Village BioPartners investment in Series C - ACELYRIN
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - ACELYRIN
OrbiMed
OrbiMed investment in Series C - ACELYRIN
Samsara BioCapital
Samsara BioCapital investment in Series C - ACELYRIN
Decheng Capital
Decheng Capital investment in Series C - ACELYRIN
Matrix Capital Management
Matrix Capital Management investment in Series C - ACELYRIN
venBio Partners
venBio Partners investment in Series C - ACELYRIN
Marshall Wace
Marshall Wace investment in Series C - ACELYRIN
Access Biotechnology
Access Biotechnology investment in Series C - ACELYRIN
Tybourne Capital Management
Tybourne Capital Management investment in Series C - ACELYRIN
Key Employee Changes
Official Site Inspections
http://www.acelyrin.com Semrush global rank: 5.78 M Semrush visits lastest month: 1.24 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ACELYRIN"
ACELYRIN - Crunchbase Company Profile & Funding
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the …See details»
ACELYRIN | Our Story
ACELYRIN was co-founded in 2020 by Shao-Lee Lin and Bob Carey. About . Science . Community . Investors & Media Careers. Stories. Contact Us. Our Story. Our People Careers. …See details»
ACELYRIN, INC. | Overview
Nov 13, 2024 ACELYRIN, INC. is a Los Angeles area-based late-stage clinical biopharmaceutical company – with additional operations in the San Francisco Bay area – …See details»
ACELYRIN | Our People
Executive Director and CEO of the TED Community Organization. Latest Press Releases. ACELYRIN Adopts Limited-Duration Stockholder Rights Plan ... Press Release. ACELYRIN …See details»
ACELYRIN - Funding, Financials, Valuation & Investors - Crunchbase
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies. New. Resources. ... How much funding has …See details»
Acelyrin, Inc. - AnnualReports.com
ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of …See details»
Corporate Governance | ACELYRIN, INC.
The Board of Directors of ACELYRIN, INC. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of …See details»
ACELYRIN - Org Chart, Teams, Culture & Jobs - The Org
View ACELYRIN's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
ACELYRIN - Contacts, Employees, Board Members, Advisors
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies. ... Experience the new Crunchbase, …See details»
ACELYRIN - Overview, News & Similar companies | ZoomInfo.com
Who is ACELYRIN. ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and …See details»
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical …
Feb 6, 2025 Information about ACELYRIN’s directors and executive officers is set forth in the proxy statement for ACELYRIN’s 2024 Annual Meeting of Stockholders, which was filed with …See details»
ACELYRIN, INC. Forms Scientific and Patient Advisory Board
Oct 16, 2024 Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 …See details»
ACELYRIN, INC. Provides Business Update and Highlights Key …
ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024. The company previously stated that its cash position is …See details»
ACELYRIN, INC. Announces $300 Million Series C Financing to …
Sep 13, 2022 ACELYRIN, INC. is a Los Angeles area-based biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life …See details»
Our People - ACELYRIN
The ACELYRIN Team. We are led by experienced biopharma executives with exceptional track records of building strong, innovative and diverse teams across the healthcare industry. Senior …See details»
ACELYRIN, INC. Forms Scientific and Patient Advisory Board …
Oct 16, 2024 Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 …See details»
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest …
Feb 21, 2025 ACELYRIN’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye …See details»
ACELYRIN, INC. Forms Scientific and Patient Advisory Board …
Oct 16, 2024 Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 …See details»
Alumis Inc. Reports Phase 2 and Phase 1 Clinical Data ... - Nasdaq
5 days ago Information about ACELYRIN’s directors and executive officers is set forth in the proxy statement for ACELYRIN’s 2024 Annual Meeting of Stockholders, which was filed with …See details»
Pipeline - ACELYRIN
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger. Read more . See All Press Releases . Building an innovative biopharma company that invests in, …See details»